Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

28 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Kleinschmidt-DeMasters BK, et al. Among authors: miravalle a. J Neuropathol Exp Neurol. 2012 Jul;71(7):604-17. doi: 10.1097/NEN.0b013e31825caf2c. J Neuropathol Exp Neurol. 2012. PMID: 22710964 Review.
Fortunately, rapid withdrawal of the drug and administration of plasma exchange has allowed survival in many of these patients, but a new problem, immune reconstitution inflammatory syndrome (IRIS), has emerged after drug withdrawal. This report provides an update on PML i …
Fortunately, rapid withdrawal of the drug and administration of plasma exchange has allowed survival in many of these patients, but a
Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine.
Schreiner TL, Miravalle A. Schreiner TL, et al. Among authors: miravalle a. J Cent Nerv Syst Dis. 2012 Jan 3;4:1-14. doi: 10.4137/JCNSD.S5128. Print 2012. J Cent Nerv Syst Dis. 2012. PMID: 23650463 Free PMC article.
Multiple Sclerosis (MS) is a chronic inflammatory, immune-mediated, demyelinating disorder of the central nervous system with a heterogeneous clinical presentation and pathology in which activated lymphocytes play an important role in mediating tissue damage. ...Cla …
Multiple Sclerosis (MS) is a chronic inflammatory, immune-mediated, demyelinating disorder of the central nervous system with a
Emerging therapies for treatment of multiple sclerosis.
Corboy JR, Miravalle AA. Corboy JR, et al. Among authors: miravalle aa. J Inflamm Res. 2010;3:53-9. doi: 10.2147/jir.s6558. Epub 2010 Jul 23. J Inflamm Res. 2010. PMID: 22096357 Free PMC article.
In the last decade, a new armamentarium of immune-based therapies have been developed and tested in patients with multiple sclerosis. Some of these therapies are showing a high level of efficacy, with an acceptable adverse effect profile. Because present therapies h …
In the last decade, a new armamentarium of immune-based therapies have been developed and tested in patients with multiple sclerosis. …
Recent advances in the treatment of multiple sclerosis.
Bennett JL, Miravalle AA. Bennett JL, et al. Among authors: miravalle aa. J Exp Pharmacol. 2010 Nov 2;2:155-61. doi: 10.2147/JEP.S7822. eCollection 2010. J Exp Pharmacol. 2010. PMID: 27186101 Free PMC article. Review.
Multiple sclerosis (MS) is a chronic inflammatory, immune-mediated, demyelinating, neurodegenerative disorder of the central nervous system. Despite the lack of an etiologic factor, it has been consistently demonstrated that the immune system plays a crucial role in …
Multiple sclerosis (MS) is a chronic inflammatory, immune-mediated, demyelinating, neurodegenerative disorder of the central nervous …
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.
Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Prosperini L, et al. Among authors: miravalle aa. Ther Adv Neurol Disord. 2019 Mar 29;12:1756286419837809. doi: 10.1177/1756286419837809. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 30956686 Free PMC article.
Remyelination Therapy in Multiple Sclerosis.
Harlow DE, Honce JM, Miravalle AA. Harlow DE, et al. Among authors: miravalle aa. Front Neurol. 2015 Dec 10;6:257. doi: 10.3389/fneur.2015.00257. eCollection 2015. Front Neurol. 2015. PMID: 26696956 Free PMC article. Review.
Therapeutic options in multiple sclerosis: five new things.
Miravalle A, Corboy JR. Miravalle A, et al. Neurology. 2010 Nov 2;75(18 Suppl 1):S22-7. doi: 10.1212/WNL.0b013e3181fb3676. Neurology. 2010. PMID: 21041767 Review. No abstract available.
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis.
Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, Wolinsky JS, Ziemssen T. Berger JR, et al. Among authors: miravalle a. Ann Neurol. 2010 Sep;68(3):409-11. doi: 10.1002/ana.22083. Ann Neurol. 2010. PMID: 20818795 No abstract available.
Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.
Miravalle A, Jensen R, Kinkel RP. Miravalle A, et al. Arch Neurol. 2011 Feb;68(2):186-91. doi: 10.1001/archneurol.2010.257. Epub 2010 Oct 11. Arch Neurol. 2011. PMID: 20937940
MAIN OUTCOMES MEASURES: Recurrent MS disease activity, defined as a clinically documented exacerbation with objective findings and/or the development of 1 or more new gadolinium-enhancing lesions on magnetic resonance imaging. ...
MAIN OUTCOMES MEASURES: Recurrent MS disease activity, defined as a clinically documented exacerbation with objective findings and/or …
Immune-Mediated Neurological Disorders.
Liewluck T, Miravalle A. Liewluck T, et al. Among authors: miravalle a. Curr Neurol Neurosci Rep. 2015 Sep;15(9):61. doi: 10.1007/s11910-015-0581-x. Curr Neurol Neurosci Rep. 2015. PMID: 26202897 Review.
It also provides a brief summary of current theories on autoimmunity and the role that certain environmental factors play in the development of immune-mediated neurological disorders. Recently recognized biomarkers might play a pathogenetic role or simply serve as …
It also provides a brief summary of current theories on autoimmunity and the role that certain environmental factors play in the deve …
28 results
Jump to page
Feedback